Fidelity Investments’s Adaptimmune Therapeutics ADAP Stock Holding History

Fidelity Investments’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-340,409	Closed	-$44.3K	–	5412
2025 Q3	$44.3K	Sell	340,409 -123,869	-27%	-$17K	﹤0.01%	4030
2025 Q2	$111K	Sell	464,278 -1,290,611	-74%	-$344K	﹤0.01%	3565
2025 Q1	$346K	Sell	1,754,889 -9,617	-0.5%	-$4.98K	﹤0.01%	3035
2024 Q4	$951K	Buy	1,764,506 +23,606	+1%	+$17.2K	﹤0.01%	2685
2024 Q3	$1.65M	Buy	1,740,900 +50,419	+3%	+$57.2K	﹤0.01%	2455
2024 Q2	$1.65M	Sell	1,690,481 -42,084	-2%	-$46.2K	﹤0.01%	2396
2024 Q1	$2.74M	Sell	1,732,565 -576	-0%	-$695	﹤0.01%	2244
2023 Q4	$1.37M	Hold	1,733,141	–	–	﹤0.01%	2382
2023 Q3	$1.35M	Sell	1,733,141 -449	-0%	-$377	﹤0.01%	2385
2023 Q2	$1.6M	Buy	1,733,590 +154,807	+10%	+$185K	﹤0.01%	2380
2023 Q1	$1.72M	Hold	1,578,783	–	–	﹤0.01%	2401
2022 Q4	$2.31M	Hold	1,578,783	–	–	﹤0.01%	2339
2022 Q3	$1.7M	Hold	1,578,783	–	–	﹤0.01%	2472
2022 Q2	$2.68M	Hold	1,578,783	–	–	﹤0.01%	2417
2022 Q1	$3.25M	Hold	1,578,783	–	–	﹤0.01%	2478
2021 Q4	$5.92M	Hold	1,578,783	–	–	﹤0.01%	2311
2021 Q3	$8.16M	Sell	1,578,783 -1	-0%	-$4	﹤0.01%	2195
2021 Q2	$6.73M	Buy	1,578,784 +1	+0%	+$5	﹤0.01%	2244
2021 Q1	$8.38M	Hold	1,578,783	–	–	﹤0.01%	2093
2020 Q4	$8.51M	Sell	1,578,783 -945,000	-37%	-$5.13M	﹤0.01%	2020
2020 Q3	$20.1M	Hold	2,523,783	–	–	﹤0.01%	1560
2020 Q2	$25.3M	Buy	2,523,783 +945,000	+60%	+$5.93M	﹤0.01%	1456
2020 Q1	$4.29M	Hold	1,578,783	–	–	﹤0.01%	1982
2019 Q4	$1.9M	Hold	1,578,783	–	–	﹤0.01%	2262
2019 Q3	$2.38M	Hold	1,578,783	–	–	﹤0.01%	2230
2019 Q2	$6.35M	Hold	1,578,783	–	–	﹤0.01%	2022
2019 Q1	$6.79M	Hold	1,578,783	–	–	﹤0.01%	1988
2018 Q4	$9.08M	Sell	1,578,783 -665,042	-30%	-$4.91M	﹤0.01%	1834
2018 Q3	$30.4M	Sell	2,243,825 -1,180,548	-34%	-$12.4M	﹤0.01%	1510
2018 Q2	$40.6M	Sell	3,424,373 -403,094	-11%	-$5.03M	﹤0.01%	1383
2018 Q1	$43M	Sell	3,827,467 -803,792	-17%	-$7.03M	0.01%	1371
2017 Q4	$30.9M	Sell	4,631,259 -336,291	-7%	-$2.6M	﹤0.01%	1524
2017 Q3	$40.7M	Sell	4,967,550 -294,200	-6%	-$1.84M	﹤0.01%	1400
2017 Q2	$23.6M	Sell	5,261,750 -1,019,900	-16%	-$5.33M	﹤0.01%	1613
2017 Q1	$34.6M	Sell	6,281,650 -783,530	-11%	-$3.43M	﹤0.01%	1481
2016 Q4	$28.6M	Hold	7,065,180	–	–	﹤0.01%	1541
2016 Q3	$49.8M	Hold	7,065,180	–	–	0.01%	1297
2016 Q2	$57.6M	Sell	7,065,180 -13,300	-0.2%	-$125K	0.01%	1215
2016 Q1	$57.5M	Buy	7,078,480 +486,179	+7%	+$3.98M	0.01%	1187
2015 Q4	$79.5M	Buy	6,592,301 +1,772,294	+37%	+$17.4M	0.01%	1060
2015 Q3	$57.7M	Sell	4,820,007 -1,346,786	-22%	-$19M	0.01%	1187
2015 Q2	$113M	Buy	+6,166,793	New	+$106M	0.01%	988

Other funds holding ADAP

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Fidelity Investments's ADAP Position: Q4 2025 in Review

Fidelity Investments sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 340,409 shares — an estimated $44.3K sold.

Fidelity Investments first reported a position in ADAP in Q2 2015 and held it in 42 quarters. The position peaked at $113M in Q2 2015. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

Fidelity Investments reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
Fidelity Investments sold 340,409 Adaptimmune Therapeutics shares in Q4 2025, an estimated $44.3K.
Fidelity Investments first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 42 quarters.
Fidelity Investments's Adaptimmune Therapeutics position peaked at $113M in Q2 2015.
10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Fidelity Investments's 13F filing for Q4 2025, filed 17 Feb 2026.